DOI QR코드

DOI QR Code

Analysis of Amyloid Beta 1-16 (Aβ16) Monomer and Dimer Using Electrospray Ionization Mass Spectrometry with Collision-Induced Dissociation

  • Kim, Kyoung Min (Department of Chemistry and Bioscience, Kumoh National Institute of Technology) ;
  • Kim, Ho-Tae (Department of Chemistry and Bioscience, Kumoh National Institute of Technology)
  • Received : 2022.12.02
  • Accepted : 2022.12.12
  • Published : 2022.12.31

Abstract

The monomer and dimer structures of the amyloid fragment Aβ(1-16) sequence formed in H2O were investigated using electrospray ionization mass spectrometry (MS) and tandem MS (MS/MS). Aβ16 monomers and dimers were indicated by signals representing multiple proton adduct forms, [monomer+zH]n+ (=Mz+, z = charge state) and [dimer+zH]z+ (=Dz+), in the MS spectrum. Fragment ions of monomers and dimers were observed using collision-induced dissociation MS/MS. Peptide bond dissociation was mostly observed in the D1-D7 and V11-K16 regions of the MS/MS spectra for the monomer (or dimer), regardless of the monomer (or dimer) charge state. Both covalent and non-covalent bond dissociation processes were indicated by the MS/MS results for the dimers. During the non-covalent bond dissociation process, the D3+ dimer complex was separated into two components: the M1+ and M2+ subunits. During the covalent bond dissociation of the D3+ dimer complex, the b and y fragment ions attached to the monomer, (M+b10-15)z+ and (M+y9-15)z+, were thought to originate from the dissociation of the M2+ monomer component of the (M1++M2+) complex. Two different D3+ complex geometries exist; two distinguished interaction geometries resulting from interactions between the M1+ monomer and two different regions of M2+ (the N-terminus and C-terminus) are proposed. Intricate fragmentation patterns were observed in the MS/MS spectrum of the D5+ complex. The complicated nature of the MS/MS spectrum is attributable to the coexistence of two D5+ configurations, (M1++M4+) and (M2+M3+), in the Aβ16 solution.

Keywords

Introduction

An understanding of protein misfolding is crucial to understanding the pathology of neurodegenerative diseases. One example of a misfolded protein is Aβ in Alzheimer’s disease (AD).1,2 AD is characterized by the extracellular deposition of Aβ in the form of plaques and neurofibrillary tangles of the Tau protein in the brain.3,4 In the plaque deposition of Aβ, Aβ oligomers that formed in the early stage of Aβ aggregation are considered to be the most neurotoxic agents in AD.5-8 However, the structure and formation process of Aβ oligomers are not yet understood clearly because of the metastable character of Aβ oligomers.9

Accordingly, oligomer formation processes have been studied using various experimental and theoretical methods including ion-mobility mass spectrometry,10,11 CD,12,13 NMR experiments14,15 and computer simulations.16-20 The collision cross-sections and the percentage of β-strands or α-helix content of oligomers were reported to aid in understanding or inhibiting Aβ fibril formation process. One (residues 12–24), two (residues 12–24 and 30–42), or three (1–6, 12–24, and 30–42) active regions were reported as critical interaction areas in the Aβ42 aggregation process.14,21-23 Several stable dimer conformations were also reported in a simulation study of Aβ oligomer.19,20

Short Aβ fragments (Aβ16–20, Aβ35–40, Aβ1–16, Aβ17–42, and Aβ1–28) have been studied to aid in understanding (or inhibiting) the Aβ aggregation process.24-28 However, the exact sequence of aggregation events and their role remain unclear. In particular, reports of the Aβ16 fragment, which is regarded as a potential inhibitor29,30 of Aβ aggregation, are discrepant. Some studies31,32 reported that Aβ16 fragments do not aggregate and reduce Aβ16 cytotoxicity in neuronal cells, whereas other reports state that Aβ16 aggregates and Aβ16 oligomers are cytotoxic.26,33

These conflicting experimental results were obtained using various experimental techniques. Metal (Ni, Cu, Zn, and Al, among others) ion-induced Aβ16 aggregation was also studied to understand the reactivity and functional group activity of Aβ16. The 10–16 residue region of Aβ appears to be an effective metal ion trapping unit.34,35 His6 and other carbonyl groups have also been reported as potential active regions for the metal ion binding unit.

In this study, we used collision-induced dissociation (CID) in conjunction with electrospray ionization (ESI)-mass spectrometry (MS) to obtain structural information on the Aβ16 monomer and dimer. Aβ16 dimer complexes were allowed to form in solution and were electrosprayed onto a quadrupole ion guide. ESI-MS was assumed to produce intact gas-phase dimer complex ions from the Aβ16 dimer complex in solution. A low-energy CID-tandem MS (MS/MS) method was applied to investigate the fragment ion species and patterns of the multiply charged monomers and dimers of Aβ16.

Experimental

The MS and MS/MS spectra for the Aβ16 fragmentation pattern analysis were obtained using a Thermo Finnigan LTQ mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA), which is a linear ion trap mass spectrometer equipped with an atmospheric pressure ESI source.

MS conditions

Aβ16 samples (in H2O) were introduced to the ESI interface via a direct infusion method using a microsyringe pump (Hamilton, USA) at a flow rate of 1 mL/min. The CID-MS/MS experiments were conducted at capillary temperatures of 150℃, which resulted in the best signal-to-noise ratios for the MS/MS spectra. The positive ion MS spectra were acquired over an m/z range of 100–2000 by averaging 1000–4000 scans. The MS/MS experimental conditions were as follows: ion-trap pressure, 1×10-5 Torr; activation time, 30 ms; injection time, 100–200 ms; and isolation width, 0.8–1.5 mass units. The parent Aβ16 ions were individually and manually selected and subjected to CID. The collision energies were optimized for each MS/MS experiment to obtain sufficient signal-to-noise ratios.

Reagents

The Aβ16 peptide, synthetic peptide (purity > 95%), amidated at the C-terminus (DAEFRHDSGYEVHHQK-NH2, Peptron, Daejeon, Korea), and HPLC-grade H2O (Merck Ltd., Korea) were used in the experiments. Aβ16 peptides were dissolved in H2O to prepare 150 μM solutions. Solutions were prepared to achieve sufficient D5+ ion intensity in the CID-MS/MS experiments. The experiments were performed within 24 h of sample preparation.

Results and Discussion

MS Spectra

Under our ESI experimental conditions, the mass spectra of the Aβ16 solutions indicated the presence of multiply charged monomers and oligomers (Figure 1). Aβ16 monomers were observed at m/z 1953.9, 977.5, 652.0, and 489.2, ranging from 1+ to 4+ and [M+H+] to [M+4H+] as multiple proton adducts forms. The Aβ16 peptide contains five basic residues (Arg5, His6, His13, His14, and Lys16) and an N-terminal position available for protonation. There are also four acidic residues (Asp1, Glu3, Asp7 and Glu11) in the Aβ16 peptide. The M5+ peak at m/z 391.6 was not observed in the ESI-MS spectrum of the Aβ16 solution (Figure 1). The M3+ monomer peak was observed with a high-intensity peak. For the oligomers, peaks were observed at m/z 1302.9, 782.2, and 1465.7, corresponding to D3+, D5+, and T4+ (T=trimer), respectively.

E1MPSV_2022_v13n4_177_f0001.png 이미지

Figure 1. ESI-MS spectrum of Aβ16 solution. Multiply charged monomers and oligomers are represented as Mz+, Dz+, and Tz+ (M = monomer, D = dimer, T = trimer, and z = charge state).

MS spectra of the Aβ16 peptide have been reported in previous studies.36-38 Oligomer complexes were not observed in these spectra because of the Aβ16 concentrations and experimental conditions. The positive charge state distribution of the Aβ16 monomers (Figure 1) is consistent with that of the previously reported MS spectrum. The new observation of D3+, D5+, and T4+ complexes indicated the possibility of aggregation of the Aβ16 peptides. The aggregation process of Aβ16 might be different from that of Aβ protein because of the extra Aβ17-42 peptide region. The configurations (up to trimer) and m/z values of the observed complexes are listed in the Supplementary Information Table S1.

MS/MS spectra of monomers

CID-MS/MS experiments were conducted to obtain structural information regarding the parent Aβ16 monomer and dimer ions. The MS/MS spectra of Aβ16 monomers are shown in Figure 2 and 3. The fragment ions were labeled with various colors and shapes based on the charge states and fragment ion species in Figure 2 and 3. The m/z values and assignments for the fragment ions in Figure 2 and 3 are presented in the Supplementary Information Table S2. These monomer MS/MS fragmentation patterns are useful for analyzing the dimer MS/MS spectrum, according to the charge state. The similar fragment ions of M2+, M3+, and M4+ monomers have been reported under different experimental conditions (in CH3OH:H2O 97:3 solution).36 The MS/MS fragment ion species shown in Figure 2 and 3 are similar to those of previously reported spectra. However, some fragment ions observed in this study have not been reported previously (including b133+, b143+, b153+, shown in Figure 2b, y133+, b92+, shown in Figure 3a, and y143+, shown in Figure 3b). In the MS/MS spectrum for Aβ16 M1+ and M2+ (Figure 2), we observed high-intensity fragment ions at the peptide bonds of the N-terminus (D1–D7) and C-terminus (V11–K16) region. The peptide bond dissociation between D7 and S8, corresponding to the b7 and y9 ions, was also observed as another characteristic dissociation channel in the CID process of M1+ or M2+ parent ions. The dissociation process in the central region, residues S8–Y10, cannot be observed in the monomer spectra (Figure 2). However, we observed distinctive fragment ions, originating from the S8–Y10 central region, in the MS/MS spectrum of M3+ (Figure 3a). The (b82+–b102+) fragment ions were observed by a part of the (2+) bu ion series peaks at u = 7–15. The (2+) bu ion series peaks at u = 7–15, which were observed at high intensities, are the characteristic ion series observed in the MS/MS spectrum of M3+ (Figure 3a). These ion series were only observed in the MS/MS spectrum of M3+ among four monomer parent ions (M1+–M4+). The b or y fragment ions from the peptide bonds of the N-terminus and C-terminus regions are also observed in Figure 3 with (+1) to (+4) charge states. The observed fragment ions are listed in Table 1.

E1MPSV_2022_v13n4_177_f0002.png 이미지

Figure 2. MS/MS spectra of monomers of Aβ16 (a) M1+ and (b) M2+. (1+) b fragment ions are indicated by blue empty circle and (1+) y fragment ions are indicated by red empty circle at top of peak. (2+) b and y fragment ions are indicated by filled circles.

E1MPSV_2022_v13n4_177_f0003.png 이미지

Figure 3. MS/MS spectra of (a) M3+ and (b) M4+ monomers. (1+) b fragment series peaks are indicated by empty blue circles and (1+) y fragment series peaks are indicated by empty red circles at top of peak. (2+) b and y fragment ions are indicated by filled circles, (3+) b and y fragment ions by filled triangles, and (4+) b and y fragment ions by filled squares at top of peak.

Table 1. Comparison of MS/MS fragment ions of Aβ16 monomers and dimers. b and y ions were observed in MS/MS spectrum for monomers and b, y, (M+ b), and (M+ y) fragment ions were observed in MS/MS spectrum for dimers.

E1MPSV_2022_v13n4_177_t0002.png 이미지

MS/MS spectra of the dimers

Both covalent and non-covalent bond dissociation were indicated by the MS/MS spectra of the dimers (Figure 4). During the non-covalent bond dissociation process, the D3+ dimer complex was separated into two components, M1+ and M2+, which produced high-intensity peaks (Figure 4a). The D3+ complex is most likely composed of (M1++M2+), rather than (M0 +M3+) complex geometry. In the case of the D5+ complex, M2+ and M3+ subunits were indicated by low-intensity peaks under our low-energy CID conditions (Figure 4b). However, the non-covalent bond dissociation resulted in the peak of the M1+ or M4+ subunit ions was not observed in Figure 4b. The charge state of parent ion is most likely crucial to the non-covalent bond dissociation process under our low-energy CID conditions. The possibility of the conformational change could also be existed in the CID thermal energy process.

E1MPSV_2022_v13n4_177_f0004.png 이미지

Figure 4. MS/MS spectra of Aβ16 (a) D3+ parent ion and (b) D5+. [M+ b, y ions]4+ fragment ions are indicated by blue or red filled squares, [M+ b, y ions]3+ by blue or red filled triangles, [M+ b, y ions]2+ by blue or red filled circles, and [b, y ions]1+ by blue or red empty circles at top of peaks.

During the covalent bond dissociation process, the D3+ MS/MS spectrum (Figure 4a) showed three fragment ion series, ① singly charged b5–b7 ions, ② doubly or triply charged [(M1+)+b11]2+–[(M1+)+b14]2+ and [(M1+)+b14]3+–[(M1+)+b15]3+ ions, and ③ doubly or triply charged [(M1+)+y11]2+–[(M1+)+y9]2+ and [(M1+)+y15] 3+–[(M1+)+y13]3+ fragment ions. The fragmentation patterns of the ①, ②, and ③ series are exactly the same as those shown in the M2+ MS/MS spectrum (Figure 2b), except for (M1+) component in the ② and ③ fragment ion series. Therefore, it is expected that the observed CID-MS/MS fragmentation pattern shown in Figure 4a originates from the M2+ monomer component of the (M1++M2+) dimer geometry. The entire M1+ component is completely conserved throughout the MS/MS dissociation of the D3+ complex.

The two proposed Aβ16 D3+ structures are shown in Scheme 1, based on observations of the ①, ②, and ③ ion series. The two proposed geometric configurations of the D3+ complex presumably coexist in the Aβ16 solution. The D3+ complex geometry shown in Scheme 1a is a likely candidate to explain the series ① or ③ fragment ion patterns, whereas the Scheme 1b geometry explains the series ② fragment ion patterns.

E1MPSV_2022_v13n4_177_f0005.png 이미지

Scheme 1. Schematics of proposed Aβ16 D3+ complex. M1+ monomer interacts at (a) the C-terminus region of M2+ monomer and (b) N-terminus region of M2+ monomer.

The Scheme 1b geometry of D3+ complex is not appropriate for explaining the singly charged b5–b7 ions in ① pattern because the fragile R5–D7 region of M2+ is blocked by the attachment of M1+, which inhibits the dissociation of the fragile R5–D7 region of M2+. Judging from the common observation of singly or doubly charged b5–b7 ions in the MS/MS spectra of M1+–M4+, the R5–D7 region is prone to dissociation in the Aβ16 complex.

Therefore, it is deduced that the singly charged b5–b7 ions in ① pattern were resulted from the Scheme 1a geometry of D3+ complex because there is no interaction between M1+ component and the fragile R5–D7 region of M2+. The possible dissociation channels are indicated by arrows in Scheme 1. If the M1+ component is attached to the restricted D1–F4 region of M2+ in the Scheme 1b geometry, the singly charged b5–b7 ions of ① pattern could be differently observed, resulted in the [M1++b5]–[M1++b7] attached ions. However, the attached fragment ions [M1++b5]–[M1++b7] were not observed in the D3+ MS/MS spectrum (Figure 4a).

Notably, fragment ion series ② in the D3+ MS/MS spectrum is low intensity. The intensities of the [M+b11]2+– [M+b14]2+ and [M+b14]3+–[M+b15]3+ monomer attached ions were significantly lower than those of (b111+–b141+) and (b142+–b152+), as shown in Figure 2b.

In fragment ion series of ③ pattern, the [M+y9]2+ ion is a counter ion to the b71+ fragment ion in the D7–S8 peptide bond dissociation process of the D3+ complex illustrated in Scheme 1a. The high intensities of the [M+y9]2+ and b71+ ions suggested that the D7–S8 peptide bond is one of the weak bonds in the D3+ complex of Scheme 1a, similar to how the D7–S8 peptide bond is one of the weak bonds in the M2+ monomer.

According to the difference in the intensities of ② and ③ patterns (Figure 4a), it is presumed that the complex formation efficiency of Scheme 1a geometry is better than that of Scheme 1b geometry. Consequently, we believe that the geometry proposed in Scheme 1a is the major species of D3+ complex in the Aβ16 solution.

In the MS/MS spectrum of the D5+ complex (Figure 4b), intricate fragmentation patterns resulting from the covalent bond dissociation process were observed. Two characteristic fragmentation patterns are observed in Figure 4b, ④ [(M1+)+(y133+)]4+ and [(M1+)+(y143+)]4+ and ⑤ [(M2+) +(b112+)]4+–[(M2+)+(b152+)]4+ fragment ions. The fragment ion series and intensities of ④ pattern or ⑤ pattern are consistent to those of the M4+ or M3+ spectrum (Figure 3) except (M1+) or (M2+) monomer attachment in the ④ and ⑤ fragment ions. Therefore, the fragment ions of ④ pattern were assigned to the fragments resulting from the dissociation of the M4+ monomer component of the (M1++M4+) dimer geometry and the fragment ions of ⑤ pattern were assigned to those resulting from the dissociation of the M3+ monomer component of the (M2++M3+) dimer geometry.

The triply charged ⑥ [M+y11]3+–[M+y9]3+ and [M+b11]3+–[M+b13]3+ ion signals are commonly attributable to fragments resulting from the dissociation of the M4+ component in the (M1++M4+) or M3+ component of the (M2++M3+) dimer geometry.

However, the ⑦ (b71+, b111+, and b121+) ion signals are attributable to the fragments resulting from the dissociation of the M3+ monomer component of the (M2++M3+) dimer geometry. The (b71+, b111+, and b121+) fragment ion signals were not observed in the MS/MS spectrum for M4+ (Figure 3b). The two proposed D3+ structures (Schemes 1a and 1b) are still applicable to the D5+ structures with different combinations of (M1++M4+) or (M2++M3+) dimer geometries. Judging from the similar intensities of the signals in ④ and ⑤ patterns, no geometric preference for either (M1++M4+) or (M2++M3+) configurations was indicated.

Conclusion

CID-MS/MS experiments were conducted to obtain structural information regarding of the Aβ16 dimer complex. The D3+ complex is composed of two subunits, M1+ and M2+. The Scheme 1a geometry of D3+ complex was expected to be more favorable than the Scheme 1b geometry. The b and y fragment ions attached to the monomer, (M+ b10-15)z+ and (M+y9-15)z+, were believed to originate from the dissociation of the M2+ monomer component of the (M1++M2+) dimer geometry. Intricate fragmentation patterns were observed in the MS/MS spectrum of the D5+ complexes. The complicated nature of the MS/MS spectrum is attributable to the coexistence of two D5+ configurations, (M1++M4+) and (M2++M3+), in the Aβ16 solution.

Acknowledgement

This study was supported by the Research Fund of the Kumoh National Institute of Technology (202002270001).

Notes and references

Electronic Supplementary Information is available: [Details of any available supplementary information should be included here]. See DOI: xx.xxxx/xxxxx./

References

  1. Chiti, F.; Dobson, C. M. Annu. Rev. Biochem. 2006, 75, 333. DOI: 10.1146/annurev.biochem.75.101304.123901
  2. Shankar, G. M.; Walsh, D. M. Mol. Neurodegener. 2009, 4, 48. DOI:10.1186/1750-1326-4-48
  3. Selkoe, D. J. Physio.l Rev. 2001, 81, 741. DOI: 10.1152/physrev.2001.81.2.741
  4. Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M.-Y. Nat. Rev. Drug Discov. 2009, 8, 783. DOI: 10.1038/nrd2959.
  5. Kirkitadze, M. D.; Bitan, G.; Teplow, D. B. J. Neurosci. Res. 2002, 69, 567. DOI: 10.1002/jnr.10328
  6. Klein, W. L.; Stine, W. B.; Teplow, D. B. Neurobiol. Aging 2004, 25, 569. DOI: 10.1016/j.neurobiolaging.2004.02.010
  7. Haass, C.; Selkoe, D. J. Nat. Rev. Mol. Cell Biol. 2007, 8, 101. DOI: 10.1038/nrm2101
  8. Sengupta, U.; Nilson, A. N.; Kayed, R. EBioMedicine 2016, 6, 42. http://dx.doi.org/10.1016/j.ebiom.2016.03.035
  9. Benilova, I.; Karran, E.; De Strooper, B. Nat. Neurosci. 2012, 15, 349. DOI: 10.1038/nn.3028
  10. Pujol-Pina, R.; Vilaprinyo-Pascual, S.; Mazzucato, R.; Arcella, A.; Vilaseca, M.; Orozco, M.; Carulla, N. Scientific Reports 2015, 5, 14809. DOI: 10.1038/srep14809
  11. Bernstein, S. L.; Dupuis, N. F.; Lazo, N. D.; Wyttenbach, T,; Condron, M. M.; Bitan, G.; Teplow, D. B.; Shea, J.-E.; Ruotolo, B. T.; Robinson, C. V.; Bowers, M. T. Nat. Chem. 2009, 1, 326. DOI: 10.1038/nchem.247
  12. Kirkitadze, M. D.; Condron, M. M.; Teplow, D. B. J. Mol. Biol. 2001, 312, 1103. DOI: 10.1006/jmbi.2001.4970
  13. Ono, K.; Condron, M. M.; Teplow, D. B. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 14745. DOI: 10.1073/pnas.0905127106
  14. Petkova, A. T.; Yau, W.-M.; Tycko, R. Biochemistry 2006, 45, 498. DOI: 10.1021/bi051952q
  15. Paravastu, A. K.; Leapman, R. D.; Yau, W.-M.; Tycko, R. Proc. Natl. Acad. Sci. 2008, 105, 18349. DOI: 10.1073/pnas.0806270105
  16. Chong, S.-H.; Ham, S. Phys. Chem. Chem. Phys. 2012, 14, 1573. DOI: 10.1039/c2cp23326f
  17. Zhang, T.; Zhang, J.; Derreumaux, P.; Mu, Y. J. Phys. Chem. B 2013, 117, 3993. DOI: 10.1021/jp312573y
  18. Das, P.; Chacko, A. R.; Belfort, G. ACS Chem. Neurosci. 2017, 8, 606. DOI: 10.1021/acschemneuro.6b00357
  19. Barz, B.; Liao, Q.; Strodel, B. J. Am. Chem. Soc. 2018, 140, 319. DOI: 10.1021/jacs.7b10343
  20. Zou, Y.; Qian, Z.; Chen, Y.; Qian H.; Wei, G.; Zhang, Q. ACS Chem. Neurosci. 2019, 10, 1585. DOI: 10.1021/acschemneuro.8b00537
  21. Reinke, A. A., Ung, P. M., Quintero, J. J., Carlson, H. A. & Gestwicki, J. E. J. Am. Chem. Soc. 2010, 132, 17655. DOI: 10.1021/ja106291e
  22. Ahmed, M.; Davis, J.; Aucoin, D.; Sato, T.; Ahuja, S.; Aimoto, S.; Elliott, J. I.; Van Nostrand, W. E.; Smith, S. O. Nat. Struct. Mol. Biol. 2010, 17, 561. DOI: 10.1038/nsmb.1799
  23. Haupt, C.; Leppert, J.; Rcnicke, R.; Meinhardt, J.; Yadav, J. K. Angew. Chem. Int. Ed. Engl. 2012, 51, 1576. DOI: 10.1002/anie.201105638
  24. Castelletto, V.; Ryumin, P.; Cramer, R.; Hamley, I. W.; Taylor, M.; Allsop, D.; Reza, M.; Ruokolainen, J.; Arnold, T.; Hermida-Merino, D.; Garcia, C. I.; Leal, M. C.; Castano, E. Scientific Reports 2017, 7, 43637. DOI: 10.1038/srep43637
  25. Berhanu, W. M.; Masunov, A. E. J. Mol. Model 2011, 17, 2423. DOI: 10.1007/s00894-010-0912-4
  26. M. Shabestari, M.; Plug, T.; Motazacker, M. M.; Meeuwenoord, N. J.; Filippov, D. V.; Meijers, J. C. M.; Huber, M. Appl. Magn. Reson. 2013, 44, 1167. DOI: 10.1007/s00723-013-0469-3
  27. Kuhn, A. J.; Abrams, B. S.; Knowlton, S.; Raskatov, J. A. ACS Chem. Neurosci. 2020, 11, 1539. DOI: 10.1021/acschemneuro.0c00160
  28. Jiang, D.; Men, L.; Wang, J.; Zhang, Y.; Chickenyen, S.; Wang, Y.; Zhou, F. Biochemistry 2007, 46, 9270. DOI: 10.1021/bi700508n
  29. A. Awasthi, A.; Matsunaga, Y.; Yamada, T. Exp. Neurol. 2005, 196, 282. DOI: 10.1016/j.expneurol.2005.08.001
  30. Y. Matsunaga, Y.; Fujii, A.; Awasthi, A.; Yokotani, J.; Takakura, T.; Yamada, T.; Regul. Pept. 2004, 120, 227. DOI: 10.1016/j.regpep.2004.03.013
  31. Liao, M.Q.; Tzeng, Y.J.; Chang, L.Y.; Huang, H.B.; Lin, T.H.; Chyan, C.L.; Chen, Y.C. FEBS Lett. 2007, 581, 1161. DOI: 10.1016/j.febslet.2007.02.026
  32. Liu, R.; McAllister, C.; Lyubchenko, Y.; Sierks, M.R. J. Neurosci. Res. 2004, 75, 162. https://doi.org/10.1002/jnr.10859
  33. Du, X.T.; Wang, L.; Wang, Y.J.; Andreasen, M.; Zhan, D.W.; Feng, Y.; Li, M.; Zhao, M.; Otzen, D.; Xue, D.; Yang, Y.; Liu, R.T. J. Alzheimer's Dis. 2011, 27, 401. DOI: 10.3233/JAD-2011-110476
  34. Furlan, S.; Hureau, C.; Faller, P.; La Penna, G. J Phys Chem B 2010, 114, 15119. DOI: 10.1021/jp102928h
  35. Istrate, A. N.; Kozin, S. A.; Zhokhov, S. S.; Mantsyzov, A. B.; Kechko, O. I.; Pastore, A.; Makarov, A. A.; Polshakov, V. I. Scientific Reports 2016, 6, 21734. DOI: 10.1038/srep21734
  36. Zirah, S.; Rebuffat, S.; Kozin, S. A.; Debey, P.; Fournier, F.; Lesage, D.; Tabet, J.-C. Int. J. Mass Spectrom. 2003, 228, 999. DOI: 10.1016/S1387-3806(03)00221-5
  37. Ma, Q.-F.; Hu, J.; Wu, W.-H.; Liu, H.-D.; Du, J.-T.; Fu, Y.; Wu, Y.-W.; Lei, P.; Zhao, Y.-F.; Li, Y.-M. Biopolymers, 2006, 83, 20. DOI: 10.1002/bip.20523
  38. Li, J.; Lyu, W.; Rossetti, G.; Konijnenberg, A.; Natalello, A.; Ippoliti, E.; Orozco, M.; Sobott, F.; Grandori, R.; Carloni, P. J. Phys. Chem. Lett. 2017, 8, 1105. DOI: 10.1021/acs.jpclett.7b00127